Impedimed Limited · ASX:IPD
Impedimed — Shareholder Meeting (October 2022)
10 slides from Impedimed's shareholder meeting presentation, Oct 26, 2022
Slide 1: 2022 Annual General Meeting – Interim CEO's Presentation
26 October 2022 For personal use only ASX ANNOUNCEMENT 2022 Annual General Meeting – Interim CEO’s Presentation ImpediMed Limited (ImpediMed) (ASX:IPD) provides the attached Interim CEO’s presentation to be delivered at today’s Annual General Meeting commencing at 9.00am AEDT. Authorised for release
Slide 2: For personal use only
date when made. ImpediMed does not assume any obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements
Slide 3: Annual General Meeting
For personal use only ANNUAL GENERAL MEETING 26 October 2022 ASX:IPD
Slide 4: Disclaimer
Disclaimer • To the extent permitted by law, no responsibility for any loss For personal use only • The material contained in this document is a presentation of general information about the activities of ImpediMed Limited arising in any way (including by way of negligence) from anyone (“ImpediMed”)
Slide 5: Forward Looking Statements
Forward Looking Statements For personal use only • Certain statements in this presentation may constitute forward- • There can be no assurance that any existing or future regulatory looking statements or statements about future matters that are filings will satisfy the relevant authorities’ requirem
Slide 6: Focus Areas
FOCUS AREAS For personal use only Dave Anderson Reimbursement Sound Financial Position Background Critical to Success through to Break-even • Dave Anderson, Interim CEO and Director • CAP program delivering results that • Sound financial position, with $34.9 • Board Member since April 2020 position
Slide 7: FY'22 & Q1 FY'23 SOZO Business Performance
FY’22 & Q1 FY’23 SOZO BUSINESS PERFORMANCE SOZO Revenue For personal use only Revenue Metrics (Excluding Legacy) $2,700,000 • Incremental growth continues prior to full reimbursement • Record results for Total Revenue, SOZO Revenue and SOZO SaaS Revenue • Total Revenue for FY’22 of $10.6 million, an
Slide 8: SOZO Business Performance
SOZO BUSINESS PERFORMANCE Strength of renewals and low churn helping to drive growth For personal use only • 38% Average Monthly License Fee increase across US renewal contracts in Q1 FY’23 • This is up from the 34% increase achieved in Q4 FY’22 • Expectation for continued renewal increases for this
Slide 9: Focus on Large Corporate Accounts
FOCUS ON LARGE CORPORATE ACCOUNTS Assembling the tools to accelerate growth Key IDNs, NCCN Institutions or Corporate Accounts added For personal use only or extended in past 2 quarters: • IDN, Corporate Account and NCCN Institution client base expanding: • In 19 of 31 NCCN Institutions • In 16 of th
Slide 10: Reimbursement the Key - Dual Path Approach
REIMBURSEMENT THE KEY - DUAL PATH APPROACH For personal use only 1. Private Payor Reimbursement / Coverage 2. NCCN Guidelines® • Case Assistance Program (CAP) continuing to deliver results • CAP produces the appeal wins needed to obtain coverage policies with health • NCCN Guidelines inclusion would